Seminars in Oncology
Volume 38, Issue 6 , Pages 734-742, December 2011

Alterations of MicroRNAs Contribute to Colon Carcinogenesis

  • Aaron J. Schetter
  • ,
  • Curtis C. Harris

      Affiliations

    • Corresponding Author InformationAddress correspondence to Curtis C Harris, MD, Laboratory of Human Carcinogenesis, National Cancer Institute, 37 Convent Dr, Room 3068A, MSC 4258, Bethesda, MD 20892-4258

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

MicroRNAs are being evaluated as biomarkers and therapeutic targets for colon cancer. MicroRNAs have a functional role in the initiation and progression of colon cancer. Altered microRNA expression is found in tumors and their expression patterns may serve as useful cancer biomarkers. Polymorphisms in microRNAs or microRNA binding sites may modify the risk of developing cancer. As we continue to improve our understanding of the role for microRNAs in the initiation and progression of cancer, one goal is to gain insights that will allow for the development of microRNAs as biomarkers and therapeutic targets for cancer. This review provides a current understanding of the connection between microRNAs and colon cancer. We will cover evidence that global microRNA expression patterns are altered in colon tumors, that specific microRNAs have a functional role in colon carcinogenesis, that polymorphisms in microRNAs may be associated with risk of colon cancer, and the potential for using circulating microRNAs as a noninvasive biomarker for the detection of cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest: none

PII: S0093-7754(11)00217-X

doi:10.1053/j.seminoncol.2011.08.009

Seminars in Oncology
Volume 38, Issue 6 , Pages 734-742, December 2011